Skip to main content

Research Repository

Advanced Search

All Outputs (44)

Overexpression of the cancer stem cell marker CD133 confers a poor prognosis in invasive breast cancer (2018)
Journal Article
Joseph, C., Arshad, M., Kurozomi, S., Althobiti, M., Miligy, I. M., Al-Izzi, S., …Rakha, E. A. (2019). Overexpression of the cancer stem cell marker CD133 confers a poor prognosis in invasive breast cancer. Breast Cancer Research and Treatment, 174(2), 387-399. https://doi.org/10.1007/s10549-018-05085-9

Purpose CD133/ prominin 1 is a cancer stem cell marker associated with cancer progression and patient outcome in a variety of solid tumours, but its role in invasive breast cancer (BC) remains obscure. The current study aims to assess the prognostic... Read More about Overexpression of the cancer stem cell marker CD133 confers a poor prognosis in invasive breast cancer.

Connexin 43 is an independent predictor of patient outcome in breast cancer patients (2018)
Journal Article
Chasampalioti, M., Green, A. R., Ellis, I. O., Rakha, E. A., Jackson, A. M., Spendlove, I., & Ramage, J. M. (2019). Connexin 43 is an independent predictor of patient outcome in breast cancer patients. Breast Cancer Research and Treatment, 174(1), 93-102. https://doi.org/10.1007/s10549-018-5063-9

Purpose Gap junctions are specialized membrane structures that form channels between adjacent cells allowing cell communication. Gap junctions and specifically Connexin 43 (Cx43) are down-regulated in cancer; however, there are contrasting reports... Read More about Connexin 43 is an independent predictor of patient outcome in breast cancer patients.

Glutamate dehydrogenase (GLUD1) expression in breast cancer (2018)
Journal Article
Craze, M. L., El-Ansari, R., Aleskandarany, M. A., Cheng, K. W., Al-Farsi, L., Masisi, B., …Green, A. R. (2019). Glutamate dehydrogenase (GLUD1) expression in breast cancer. Breast Cancer Research and Treatment, 174(1), 79–91. https://doi.org/10.1007/s10549-018-5060-z

Dysregulated cellular metabolism is regarded as one of the hallmarks of cancer with some tumours utilising the glutamine metabolism pathway for their sustained proliferation and survival. Glutamate dehydrogenase (GLUD1) is a key enzyme in glutaminoly... Read More about Glutamate dehydrogenase (GLUD1) expression in breast cancer.

Legumain is an independent predictor for invasive recurrence in breast ductal carcinoma in situ (2018)
Journal Article
Toss, M. S., Miligy, I. M., Gorringe, K. L., McCaffrey, L., Alkawaz, A., Abidi, A., …Rakha, E. A. (2019). Legumain is an independent predictor for invasive recurrence in breast ductal carcinoma in situ. Modern Pathology, 32, 639-649. https://doi.org/10.1038/s41379-018-0180-x

© 2018, United States & Canadian Academy of Pathology. Legumain is a proteolytic enzyme that plays a role in the regulation of cell proliferation in invasive breast cancer. Studies evaluating its role in ductal carcinoma in situ (DCIS) are lacking.... Read More about Legumain is an independent predictor for invasive recurrence in breast ductal carcinoma in situ.

Prolyl-4-hydroxylase ? subunit 2 (P4HA2) expression is a predictor of poor outcome in breast ductal carcinoma in situ (DCIS) (2018)
Journal Article
Toss, M. S., Miligy, I. M., Gorringe, K. L., Alkawaz, A., Khout, H., Ellis, I. O., …Rakha, E. (2018). Prolyl-4-hydroxylase Α subunit 2 (P4HA2) expression is a predictor of poor outcome in breast ductal carcinoma in situ (DCIS). British Journal of Cancer, 119(12), 1518-1526. https://doi.org/10.1038/s41416-018-0337-x

© 2018, Cancer Research UK. Background: Extracellular matrix (ECM) plays a crucial role in tumour behaviour. Prolyl-4-hydroxlase-A2 (P4HA2) is a key enzyme in ECM remodelling. This study aims to evaluate the prognostic significance of P4HA2 in breast... Read More about Prolyl-4-hydroxylase ? subunit 2 (P4HA2) expression is a predictor of poor outcome in breast ductal carcinoma in situ (DCIS).

Co-expression of nuclear P38 and hormone receptors is prognostic of good long-term clinical outcome in primary breast cancer and is linked to upregulation of DNA repair (2018)
Journal Article
Johnston, S. J., Ahmad, D., Aleskandarany, M. A., Kurozumi, S., Nolan, C. C., Diez-Rodriguez, M., …Rakha, E. A. (2018). Co-expression of nuclear P38 and hormone receptors is prognostic of good long-term clinical outcome in primary breast cancer and is linked to upregulation of DNA repair. BMC Cancer, 18, Article 1027. https://doi.org/10.1186/s12885-018-4924-2

Breast tumours resembling the tall cell variant of thyroid papillary carcinoma: are they part of the papillary carcinoma spectrum or a distinct entity? (2018)
Journal Article
Toss, M., Billingham, K., Egbuniwe, I., Moreno, F., Abass, A., & Rakha, E. (2018). Breast tumours resembling the tall cell variant of thyroid papillary carcinoma: are they part of the papillary carcinoma spectrum or a distinct entity?. Pathobiology, 1-9. https://doi.org/10.1159/000490416

Background: Papillary tumours of the breast are diagnostically challenging lesions and represent a wide spectrum of diseases from papilloma to invasive papillary carcinoma. A rare subtype of breast papillary tumour resembling the tall cell variant of... Read More about Breast tumours resembling the tall cell variant of thyroid papillary carcinoma: are they part of the papillary carcinoma spectrum or a distinct entity?.

Kinesin family member-18A (KIF18A) is a predictive biomarker of poor benefit from endocrine therapy in early ER+?breast cancer (2018)
Journal Article
Alfarsi, L. H., Elansari, R., Toss, M. S., Diez-Rodriguez, M., Nolan, C. C., Ellis, I. O., …Green, A. R. (2018). Kinesin family member-18A (KIF18A) is a predictive biomarker of poor benefit from endocrine therapy in early ER+ breast cancer. Breast Cancer Research and Treatment, https://doi.org/10.1007/s10549-018-4978-5

PURPOSE: Identification of effective and reliable biomarkers that could be used to predict the efficacy of endocrine therapy is of crucial importance to the management of oestrogen receptor positive (ER+) breast cancer (BC). KIF18A, a key regulator o... Read More about Kinesin family member-18A (KIF18A) is a predictive biomarker of poor benefit from endocrine therapy in early ER+?breast cancer.

Targeting PARP1 in XRCC1-deficient sporadic invasive breast cancer or preinvasive ductal carcinoma in situ induces synthetic lethality and chemoprevention (2018)
Journal Article
Ali, R., Al-Kawaz, A., Toss, M. S., Green, A. R., Miligy, I. M., Mesquita, K. A., …Madhusudan, S. (2018). Targeting PARP1 in XRCC1-deficient sporadic invasive breast cancer or preinvasive ductal carcinoma in situ induces synthetic lethality and chemoprevention. Cancer Research, 78(24), 6818-6827. https://doi.org/10.1158/0008-5472.CAN-18-0633

© 2018 American Association for Cancer Research. Targeting PARP1 for synthetic lethality is a new strategy for breast cancers harboring germline mutations in BRCA. However, these mutations are rare, and reactivation of BRCA-mediated pathways may resu... Read More about Targeting PARP1 in XRCC1-deficient sporadic invasive breast cancer or preinvasive ductal carcinoma in situ induces synthetic lethality and chemoprevention.

Loss-of-function mutations in ATP6AP1 and ATP6AP2 in granular cell tumors (2018)
Journal Article
Pareja, F., Brandes, A. H., Basili, T., Selenica, P., Geyer, F. C., Fan, D., …Reis-Filho, J. S. (2018). Loss-of-function mutations in ATP6AP1 and ATP6AP2 in granular cell tumors. Nature Communications, 9, Article 3533. https://doi.org/10.1038/s41467-018-05886-y

Granular cell tumors (GCTs) are rare tumors that can arise in multiple anatomical locations, and are characterized by abundant intracytoplasmic granules. The genetic drivers of GCTs are currently unknown. Here, we apply whole-exome sequencing and tar... Read More about Loss-of-function mutations in ATP6AP1 and ATP6AP2 in granular cell tumors.

A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal (2018)
Journal Article
Rindi, G., Klimstra, D. S., Abedi-Ardekani, B., Asa, S. L., Bosman, F. T., Brambilla, E., …Cree, I. A. (2018). A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal. Modern Pathology, 31(12), 1770-1786. https://doi.org/10.1038/s41379-018-0110-y

© 2018, United States & Canadian Academy of Pathology. The classification of neuroendocrine neoplasms (NENs) differs between organ systems and currently causes considerable confusion. A uniform classification framework for NENs at any anatomical lo... Read More about A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal.

The role of PIP5K1?/pAKT and targeted inhibition of growth of subtypes of breast cancer using PIP5K1? inhibitor (2018)
Journal Article
Sarwar, M., Syed Khaja, A. S., Aleskandarany, M., Karlsson, R., Althobiti, M., Ødum, N., …Persson, J. L. (2019). The role of PIP5K1α/pAKT and targeted inhibition of growth of subtypes of breast cancer using PIP5K1α inhibitor. Oncogene, 38(3), 375-389. https://doi.org/10.1038/s41388-018-0438-2

© 2018, The Author(s). Despite recent improvement in adjuvant therapies, triple-negative, and ER + subtypes of breast cancer (BC) with metastatic potentials remain the leading cause of BC-related deaths. We investigated the role of phosphatidylinosi... Read More about The role of PIP5K1?/pAKT and targeted inhibition of growth of subtypes of breast cancer using PIP5K1? inhibitor.

Clinicopathological and prognostic significance of Ras association and pleckstrin homology domains 1 (RAPH1) in breast cancer (2018)
Journal Article
Kurozumi, S., Joseph, C., Sonbul, S., Aleskandarany, M. A., Pigera, M., Alsaleem, M., …Rakha, E. A. (2018). Clinicopathological and prognostic significance of Ras association and pleckstrin homology domains 1 (RAPH1) in breast cancer. Breast Cancer Research and Treatment, 172(1), 61–68. https://doi.org/10.1007/s10549-018-4891-y

BACKGROUND: Ras association and pleckstrin homology domains 1 (RAPH1) is involved in cytoskeleton regulation and re-epithelialisation in invasive carcinoma and therefore may play a key role in carcinogenesis and metastasis. We herein investigated the... Read More about Clinicopathological and prognostic significance of Ras association and pleckstrin homology domains 1 (RAPH1) in breast cancer.

The spectrum of triple-negative breast disease: high- and low-grade lesions (2018)
Journal Article
Geyer, F. C., Pareja, F., Weigelt, B., Rakha, E., Ellis, I. O., Schnitt, S. J., & Reis-Filho, J. S. (2018). The spectrum of triple-negative breast disease: high- and low-grade lesions. American Journal of Pathology, 187(10), 2139-2151. https://doi.org/10.1016/j.ajpath.2017.03.016

Triple-negative breast cancer is viewed clinically as an aggressive subgroup of breast cancer. In fact, most triple-negative breast cancers are poor-prognosis tumors with a complex genomic landscape. However, triple-negative disease is vastly heterog... Read More about The spectrum of triple-negative breast disease: high- and low-grade lesions.

Impact of breast cancer grade discordance on prediction of outcome (2018)
Journal Article
Rakha, E. A., Aleskandarany, M. A., Toss, M. S., Mongan, N., El-Sayed, M. E., Green, A. R., …Dalton, L. W. (in press). Impact of breast cancer grade discordance on prediction of outcome. Histopathology, https://doi.org/10.1111/his.13709

BACKGROUND: Histological grade is an independent prognostic variable in breast cancer (BC). Previous concordance studies of BC grade have reported moderate levels of agreement; a typical finding in morphological assessment of biological variables. Th... Read More about Impact of breast cancer grade discordance on prediction of outcome.

Intra-operative spectroscopic assessment of surgical margins during breast conserving surgery (2018)
Journal Article
Shipp, D. W., Rakha, E. A., Koloydenko, A. A., Macmillan, R. D., Ellis, I. O., & Notingher, I. (2018). Intra-operative spectroscopic assessment of surgical margins during breast conserving surgery. Breast Cancer Research, 20, https://doi.org/10.1186/s13058-018-1002-2

Background: In over 20% of breast conserving operations, postoperative pathological assessment of the excised tissue reveals positive margins, requiring additional surgery. Current techniques for intra-operative assessment of tumor margins are insuff... Read More about Intra-operative spectroscopic assessment of surgical margins during breast conserving surgery.

Breast cancer intratumour heterogeneity: current status and clinical implications (2018)
Journal Article
Joseph, C., Papadaki, A., Althobiti, M., Alsaleem, M., Aleskandarany, M. A., & Rakha, E. A. (2018). Breast cancer intratumour heterogeneity: current status and clinical implications. Histopathology, 73(5), (717-731). doi:10.1111/his.13642. ISSN 0309-0167

Breast cancer (BC) is a heterogeneous disease that varies in presentation, morphological features, behaviour, and response to therapy. High?throughput molecular profiling studies have revolutionised our understanding of BC heterogeneity, and have dem... Read More about Breast cancer intratumour heterogeneity: current status and clinical implications.

The relationship of CDK18 expression in breast cancer to clinicopathological parameters and therapeutic response (2018)
Journal Article
Barone, G., Arora, A., Ganesh, A., Abdel-Fatah, T., Moseley, P., Ali, R., …Collis, S. J. (2018). The relationship of CDK18 expression in breast cancer to clinicopathological parameters and therapeutic response. Oncotarget, 9, 29508-29524. https://doi.org/10.18632/oncotarget.25686

Background: Cyclin-Dependent Kinases (CDKs) are established anti-cancer drug targets and a new generation of CDK inhibitors are providing clinical benefits to a sub-set of breast cancer patients. We have recently shown that human CDK18 promotes effic... Read More about The relationship of CDK18 expression in breast cancer to clinicopathological parameters and therapeutic response.

Thioredoxin-interacting protein is an independent risk stratifier for breast ductal carcinoma in situ (2018)
Journal Article
Miligy, I. M., Gorringe, K. L., Toss, M. S., Al-Kawaz, A., Simpson, P., Diez-Rodriguez, M., …Rakha, E. (2018). Thioredoxin-interacting protein is an independent risk stratifier for breast ductal carcinoma in situ. Modern Pathology, 31(12), 1807-1815. https://doi.org/10.1038/s41379-018-0086-7

Current clinicopathological parameters are useful predictors of breast ductal carcinoma in situ behaviour, but they are insufficient to define high risk patients for disease progression precisely. Thioredoxin interacting protein (TXNIP) is a key play... Read More about Thioredoxin-interacting protein is an independent risk stratifier for breast ductal carcinoma in situ.